Celgene

This study follows about 665 people with myelodysplastic syndromes, beta-thalassemia, or myelofibrosis who have already taken luspatercept in earlier trials. Researchers want to see how safe the drug is over many years by tracking side effects, disease progression, and survival. …

This phase 3 trial compares a new drug, BMS-986365, against standard treatments (docetaxel or other hormone therapies) in 960 men with metastatic castration-resistant prostate cancer that has stopped responding to hormone therapy. The main goal is to see if the new drug delays ca…

This Phase 3 trial is testing whether a new drug called mezigdomide, combined with two standard drugs (bortezomib and dexamethasone), works better than the current standard combination (pomalidomide, bortezomib, and dexamethasone) for people with multiple myeloma that has come ba…

This early-stage study tests whether adding either iberdomide or CC-99282 to standard chemotherapy (R-CHOP) can safely treat people with untreated aggressive B-cell lymphoma. About 224 adults will take part. The main goals are to find the best dose and check for side effects, whi…

This study tests two drugs, mezigdomide and elranatamab, together in people with multiple myeloma that has come back or stopped responding to prior treatments. The goal is to find the safest dose and see if the combination can shrink tumors. About 62 adults will take part in this…

This Phase 3 trial compares a new drug combination (golcadomide plus rituximab) against standard treatments for people with follicular lymphoma that has come back or stopped responding to at least one prior therapy. About 400 participants will be randomly assigned to receive eith…

This study tests a drug called luspatercept in children aged 6 to 18 with beta-thalassemia, a blood disorder that often requires regular transfusions. The goal is to see if the drug is safe and can reduce the need for transfusions or raise hemoglobin levels. The trial is still re…

This program offers a special type of cell therapy (ide-cel) to people with multiple myeloma whose manufactured treatment batch didn't meet commercial standards but may still be safe and effective. Participants must be clinically stable and have no other suitable treatment option…

This study tests an experimental oral drug, BMS-986368, for treating muscle stiffness (spasticity) in people with multiple sclerosis. About 200 participants will receive one of three doses of the drug or a placebo. The goal is to see if the drug safely reduces muscle tightness an…

This study tests an experimental oral medication (BMS-986368) to reduce agitation in people with Alzheimer's disease. About 120 participants will receive either a low dose, high dose, or placebo. The main goal is to see if the drug safely decreases agitated behaviors, such as pac…

This study follows over 1,500 children and adults who previously received gene-modified T cell therapy for cancer. Researchers will track side effects, how long the modified cells last, and overall survival for up to 15 years. No new treatment is given—the goal is to understand l…

This study looks at how two other drugs (itraconazole and rifampin) change the amount of AR-LDD in the blood of healthy adult men. 42 participants will take AR-LDD alone and then with each of the other drugs to see the difference. This is a phase 1 trial with no direct treatment …